Cell Therapies Supply Chain Management Market

Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions

  • Lowest Price Guaranteed From USD 4,499

  • Published
    October 2019

  • Pages
    427

  • View Count
    19387

Example Insights

This image highlights the context of Cell Therapy Supply Chain Management Market report This image provides list of Cell Therapy Supply Chain Management Software Solutions This image highlights competitive analysis of players engaged in the domain of Cell Therapy Supply Chain Management
This image presents current market landscape of Cell Therapy Supply Chain Management Software Solution Providers This image describes the analysis of value chain and stakeholders need in Cell Therapy Supply Chain Management Market This image highlights the partnership activity undertaken by players engaged in Cell Therapy Supply Chain Management Market
This image presents the social media analysis of Cell Therapy Supply Chain Management Market This image provides information on Likely Cost Saving Potential of Cell Therapy Supply Chain Management Market- This image highlights the market segments of Cell Therapy Supply Chain Management Market

 

Report Description

Cell Therapies Supply Chain Management Market Overview

The global cell and advanced therapies supply chain management market is likely to be worth $159 million and this value is projected to reach $1,508 million by 2030, growing at an annualized rate of 25% in the given period. Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions. In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma® (2019), RECELL® System (2018), AmnioFix® (2018), EpiFix® (2018), EpiBurn® (2018), Alofisel® (2018), LUXTURNA™ (2017), Yescarta® (2017), and Kymriah® (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies. In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year.  It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025. 

The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers. These concerns are likely to escalate multi-fold when dynamic situations, such as the ongoing COVID-19 pandemic, significantly disrupt the overall supply chains. This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed. The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.

Scope of the Report

The ‘Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030’ report features an extensive study of the growing supply chain management software solutions market. The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape, featuring a comprehensive list of over 160 technological platforms that are being used to manage the cell and advanced therapies supply chain, along with information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others).
  • An insightful company competitiveness analysis, taking into consideration the supplier power (based on their employee base and years of experience in the industry) and portfolio-related parameters, such as number of software solutions offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits.
  • Comprehensive profiles of industry players that are currently offering software solutions for supply chain management, featuring an overview of the company, its financial information (if available), and a detailed description of its software system(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.
  • A detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, such as donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices.
  • A qualitative assessment of the current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / payers) involved in the cell and advanced therapies supply chain, featuring a summary of the diverse needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address such issues. 
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are engaged in this field.
  • An analysis of the partnerships that have been established in the domain, in the period between 2014 and Q3 2019, covering software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and other relevant deals.
  • A detailed analysis of the platform utilization use cases where aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019, highlighting the ways in which companies have implemented such systems to improve / optimize various supply chain-related processes of cell and advanced therapies.
  • An in-depth analysis of the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems.
  • A case study on COPs, featuring insights on their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the cell and advanced therapies supply chain. In addition, it provides a brief discussion on the growing popularity of COPs on the social media platform, Twitter.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, and TTS), [B] applications (donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), [C] modes of deployment (cloud and on-premises), [D] end users (biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: 

  • Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific)
  • Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult)
  • Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) and Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson)
  • Martin Lamb (Chief Business Officer, TrakCel)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the trending software solutions for the management of cell and advanced therapies supply chain?
  • Who are the leading industry and non-industry players in this domain?
  • What are the key challenges faced by various stakeholders in this domain?
  • What kind of partnership models are commonly adopted by stakeholders in this industry?
  • Who are the key investors in this field?
  • What is the current and likely future cost saving opportunities associated with supply chain management solutions?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographies? 
  • What factors are likely to influence the evolution of this upcoming market?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the cell and advanced therapies supply chain solutions market in the mid to long term.

Chapter 3 is an introductory chapter that presents a general overview of the cell and advanced therapies domain, along with details on the various types of such products and the current therapy landscape. It features a detailed discussion on the cell and advanced therapies supply chain and key challenges related to different processes / stakeholders involved in this segment of the industry. The chapter also provides information on various software-enabled systems, highlighting their key advantages and associated challenges. Further, the chapter describes the key growth drivers and roadblocks related to the use of such solutions in the cell and advanced therapies supply chain, offering insights on the emergence of advanced, digital technologies in the domain, as well. 

Chapter 4 includes information on more than 160 technological platforms that are currently being used for managing the critical intricacies within the cell and advanced therapies supply chain. It features detailed information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others).

Chapter 5 features an insightful competitiveness analysis of the software solutions providers based on various parameters, such as number of software systems offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits. In the chapter, stakeholder entities have been plotted on a 2X2 matrix, having a company’s Supplier Power (based on its employee base and years of experience in the industry) and Company Competitiveness as the two axes.

Chapter 6 includes elaborate profiles of companies that are currently offering core supply chain management software systems, such as EMS, IMS, LIMS, LMS, PMS, QMS, and TTS (shortlisted on the basis of company competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), and a detailed description of the platform(s). Each profile also includes a list of recent developments, highlighting key achievements, partnership activity and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.

Chapter 7 presents a brief introduction to COPs, along with insights into their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the entire cell and advanced therapies supply chain. Further, the chapter includes a brief discussion on the growing popularity of COP on the social media platform, Twitter, and presents a snapshot of how the public opinion about such technological solutions has evolved in the period 2014-2018. In addition, the chapter features detailed profiles of all the industry players that are currently offering COPs for supply chain management. For each of these companies, we have presented detailed profiles, featuring an overview of the company, its financial information (if available), and a detailed description of the platform(s). Each profile also includes a list of recent developments, highlighting key achievements, partnership activity and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.

Chapter 8 provides information on funding instances and investments that have been made within the cell and advanced therapies supply chain management market. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies between 2014 and Q3 2019, highlighting the growing interest of the venture capital community and other strategic investors in this domain. 

Chapter 9 features an elaborate discussion and analysis of partnerships / collaborations that have been established in the domain in the period between 2014 and Q3 2019. It includes a brief description of various types of partnership models (such as software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances in this industry. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 presents a detailed analysis of platform utilization use cases where the aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019. It includes a brief discussion on the ways in which companies have implemented such software solutions to improve / optimize various supply chain-related processes of cell and advanced therapies.

Chapter 11 provides a qualitative assessment of the current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / payers) involved in the cell and advanced therapies supply chain. It also presents a summary of the diverse needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address the aforementioned issues.

Chapter 12 presents a detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, such as donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices.

Chapter 13 features an insightful analysis, highlighting the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems.

Chapter 14 features a comprehensive market forecast, highlighting the future potential of the supply chain management software solutions market till 2030, based on multiple parameters, such as number of cell and advanced therapies in development, expected pricing, likely adoption rates, and cost saving opportunity from different software systems. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, and TTS), [B] applications (donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), [C] modes of deployment (cloud and on-premises), [D] end users (biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.

Chapter 15 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific), Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult), Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) and Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson), and Martin Lamb (Chief Business Officer, TrakCel)

Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is an appendix, which provides a comprehensive list of technological solutions / software systems that are being used to effectively manage and streamline the supply chain processes of the overall healthcare industry.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. An Introduction to Cell and Advanced Therapies
3.2.1. Classification of Advanced Therapy Medicinal Products
3.2.2. Current Market Landscape
 
3.3. Cell and Advanced Therapies Supply Chain
3.3.1. Key Processes
3.3.1.1. Donor Eligibility Assessment
3.3.1.2. Sample Collection
3.3.1.3. Manufacturing
3.3.1.4. Logistics
3.3.1.5. Patient Verification and Treatment Follow-up
 
3.3.2. Challenges Associated with the Cell and Advanced Therapies Supply Chain
3.3.2.1. Process Standardization
3.3.2.2. Process Qualification
3.3.2.3. Chain of Custody Documentation
3.3.2.4. Capacity Scheduling and Resource Utilization
3.3.2.5. Packaging and Shipping Qualification
3.3.2.6. Validation of Storage Containers
 
3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management
3.4.1. Cell Orchestration Platform
3.4.2. Enterprise Manufacturing System
3.4.3. Inventory Management System
3.4.4. Laboratory Information Management System
3.4.5. Logistics Management System
3.4.6. Patient Management System
3.4.7. Quality Management System
3.4.8. Tracking and Tracing System
 
3.5. Growth Drivers and Roadblocks
3.6. Emergence of Digital Technologies in Supply Chain Management
3.6.1. Blockchain Technology
3.6.2. Internet of Things
3.6.3. Augmented Reality
3.6.4. Big Data Analytics
3.6.5. Artificial Intelligence
 
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape
4.2.1. Analysis by Type of Software Solution
4.2.2. Analysis by Key Specification and Benefit
4.3.3. Analysis by Application
4.3.4. Analysis by End User
4.3.5. Analysis by Mode of Deployment
4.3.6. Analysis by Scale of Management
4.3.7. Analysis by Regulatory Certifications / Accreditations
 
4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Location of Headquarters
4.2.3. Analysis by Size of Company
4.3.4. Analysis by Support Services Offered
4.3.5. Leading Developers: Analysis by Number of Software Solutions
 
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Overview of Supply Chain Management Software Solution Providers
5.4.1. Small-sized Companies
5.4.2. Mid-sized Companies
5.4.3. Large Companies
 
6. CORE SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Brooks Life Sciences
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. BiobankPro®: Software Description
6.2.4. Recent Developments and Future Outlook
 
6.3. Cryoport
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Cryoportal®: Software Description
6.3.4. Recent Developments and Future Outlook
 
6.4. MasterControl
6.4.1. Company Overview
6.4.2. MasterControl Platform™: Software Description
6.4.3. Recent Developments and Future Outlook
 
6.5. SAP
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. SAP S/4HANA®: Software Description
6.5.4. Recent Development and Future Outlook
 
6.6. Savsu Technologies
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. evo® Cold Chain 2.0™: Software Description
6.6.4. Recent Development and Future Outlook
 
6.7. TraceLink
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Digital Supply Chain Platform: Software Description
6.7.4. Recent Developments and Future Outlook
 
7. CELL ORCHESTRATION PLATFORMS: EMERGING TRENDS AND PROFILES OF KEY PLAYERS
7.1. Chapter Overview
7.2. Supply Chain Orchestration Platforms
7.2.1. Key Functions of Supply Chain Orchestration Platforms
7.2.2. Advantages of Supply Chain Orchestration Platforms
7.2.3. Supply Chain Orchestration Platform Implementation Strategies
7.2.3.1. Building the Required Foundation
7.2.3.2. Incorporating an Appropriate Scheduling System
7.2.3.3. Integration with Core Systems / Processes
 
7.3. Supply Chain Orchestration Platform: Trends on Twitter
7.3.1. Scope and Methodology
7.3.2. Historical Trends in Volume of Tweets
7.3.3. Popular Keywords
 
7.4. Key Industry Players
7.4.1. Be The Match BioTherapies®
7.4.1.1. Company Overview
7.4.1.2. Financial Information
7.4.1.3. MatchSource®: Software Description
7.4.1.4. Recent Developments and Future Outlook
 
7.4.2. Clarkston Consulting
7.4.2.1. Company Overview
7.4.2.2. Cell Therapy Orchestration Platform: Software Description
7.4.2.3. Recent Developments and Future Outlook
 
7.4.3. Haemonetics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. EdgeCell®: Software Description
7.4.3.4. Recent Developments and Future Outlook
 
7.4.4. Hypertrust Patient Data Care
7.4.4.1. Company Overview
7.4.4.2. Hypertrust X-Chain: Software Description
7.4.4.3. Recent Developments and Future Outlook
 
7.4.5. Lykan Bioscience
7.4.5.1. Company Overview
7.4.5.2. Unnamed Platform: Software Description
7.4.5.3. Recent Developments and Future Outlook
 
7.4.6. MAK-SYSTEM
7.4.6.1. Company Overview
7.4.6.2. T.C.S.: Software Description
7.4.6.3. Recent Developments and Future Outlook
 
7.4.7. sedApta Group
7.4.7.1. Company Overview
7.4.7.2. O.S.A.: Software Description
7.4.7.3. Recent Developments and Future Outlook
 
7.4.8. Stafa Cellular Therapy
7.4.8.1. Company Overview
7.4.8.2. Stafa Cellular Therapy Lab: Software Description
7.4.8.3. Recent Developments and Future Outlook
 
7.4.9. Title 21 Health Solutions
7.4.9.1. Company Overview
7.4.9.2. Cell Therapy Software: Software Description
7.4.9.3. Recent Developments and Future Outlook
 
7.4.10. TrakCel
7.4.10.1. Company Overview
7.4.10.2. Financial Information
7.4.10.3. TrakCel™ Cell Orchestration Platform: Software Description
7.4.10.4. Recent Developments and Future Outlook
 
7.4.11. Vineti
7.4.11.1. Company Overview
7.4.11.2. Financial Information
7.4.11.3. Personalized Therapy Management Software: Software Description
7.4.11.4. Recent Developments and Future Outlook
 
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Cell and Advanced Therapies Supply Chain Management: Recent Funding Instances
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions
8.3.5. Most Active Players: Analysis by Amount Invested
8.3.6. Most Active Investors: Analysis by Participation
8.3.7. Geographical Analysis by Amount Invested
8.4. Concluding Remarks
 
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Partner’s Focus Area
9.3.4. Analysis by Type of Software Solution
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Analysis by Regions
9.3.6.1. Most Active Players: Regional Analysis by Number of Partnerships
9.3.6.2. Intercontinental and Intracontinental Agreements
 
10. PLATFORM UTILIZATION USE CASES
10.1. Chapter Overview
10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases
10.2.1. Analysis by Year of Utilization
10.2.2. Analysis by User’s Focus Area
10.2.3. Analysis by Type of Software Solution
10.2.4. Most Active Players: Analysis by Number of Utilization Instances
10.2.5. Most Active Players: Regional Analysis by Number of Utilization Instances
 
11. VALUE CHAIN ANALYSIS
11.1. Chapter Overview
11.2. Cell and Advanced Therapies Value Chain
11.2. Cell and Advanced Therapies Value Chain: Cost Distribution
11.3.1. Donor Eligibility Assessment
11.3.2. Sample Collection
11.3.3. Manufacturing
11.3.4. Logistics
11.3.5. Patient Verification and Treatment Follow-up
 
12. STAKEHOLDER NEEDS ANALYSIS
12.1. Chapter Overview
12.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders
12.2.1. Comparison of Stakeholder Needs
 
13. COST SAVINGS ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030
13.3.1. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030
13.3.2. Cost Saving Potential in Sample Collection, 2019-2030
13.3.3. Cost Saving Potential in Manufacturing, 2019-2030
13.3.4. Cost Saving Potential in Logistics, 2019-2030
13.3.5. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030
 
14. MARKET FORECAST
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030
 
14.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application
14.3.1.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030
14.3.1.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030
14.3.1.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
14.3.1.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
14.3.1.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
 
14.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User
14.3.2.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030
14.3.2.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, 2019-2030
14.3.2.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, 2019-2030
14.3.2.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030
14.3.2.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, 2019-2030
 
14.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution
14.3.3.1. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.2. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.3. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.4. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.5. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.6. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.7. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
 
14.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment
14.3.4.1. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030
14.3.4.2. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030
 
14.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography
14.3.5.1. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030
14.3.5.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030
14.3.5.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030
 
14.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment
14.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030
14.4.1.1. Patient Management Systems Market for Donor Eligibility Assessment, 2019-2030
14.4.1.1.1. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030
14.4.1.1.2. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030
14.4.1.2. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, 2019-2030
14.4.1.2.1. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030
14.4.1.2.2. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030
 
14.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030
14.4.2.1. Inventory Management Systems Market for Sample Collection, 2019-2030
14.4.2.1.1. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.1.2. Inventory Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.2. Laboratory Information Management Systems Market for Sample Collection, 2019-2030
14.4.2.2.1. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.2.2. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.3. Logistics Management Systems Market for Sample Collection, 2019-2030
14.4.2.3.1. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.3.2. Logistics Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.4. Quality Management Systems Market for Sample Collection, 2019-2030
14.4.2.4.1. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.4.2. Quality Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.5. Supply Chain Orchestration Platforms Market for Sample Collection, 2019-2030
14.4.2.5.1. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.5.2. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, 2019-2030
 
14.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
14.4.3.1. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030
14.4.3.1.1. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.1.2. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.2. Inventory Management Systems Market for Manufacturing, 2019-2030
14.4.3.2.1. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.2.2. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.3. Laboratory Information Management Systems Market for Manufacturing, 2019-2030
14.4.3.3.1. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.3.2. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.4. Quality Management Systems Market for Manufacturing, 2019-2030
14.4.3.4.1. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.4.2. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.5. Supply Chain Orchestration Platforms Market for Manufacturing, 2019-2030
14.4.3.5.1. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.5.2. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, 2019-2030
 
14.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
14.4.4.1. Logistics Management Systems Market for Logistics, 2019-2030
14.4.4.1.1. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030
14.4.4.1.2. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030
14.4.4.2. Supply Chain Orchestration Platforms Market for Logistics, 2019-2030
14.4.4.2.1. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
14.4.4.2.2. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
 
14.4.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.1.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
14.4.5.1.2. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
14.4.5.2. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.2.1. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
14.4.5.2.2. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
 
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Thermo Fisher Scientific
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Bryan Poltilove, Vice President and General Manager
 
15.3. Cell and Gene Therapy Catapult
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
 
15.4. McKesson
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Jill Maddux, Director, Cell and Gene Therapy Product Strategy, and Divya Iyer, Senior Director, Corporate Strategy and Business Development
 
15.5. TrakCel
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Martin Lamb, Chief Business Officer
 
16. CONCLUDING REMARKS
16.1. Chapter Overview
16.2. Key Takeaways
 
17. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS
 
18. APPENDIX 2: TABULATED DATA
 
19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS 

List of Figures

Figure 3.1. Classification of Advanced Therapy Medicinal Products
Figure 3.2. Market Access Landscape of Key Cell and Advanced Therapies across Different Geographies
Figure 3.3. Key Processes of Cell and Advanced Therapies Supply Chain
Figure 3.4. Responsibilities of Stakeholders Involved in Cell and Advanced Therapies Supply Chain
Figure 3.4. Key Steps Involved in the Manufacturing of Cell and Advanced Therapies
Figure 3.5. Keys Steps Involved in Logistics Operations of Autologous Therapies
Figure 3.6. Comparison of Logistics Processes for Autologous and Allogeneic Therapies
Figure 3.7. Key Challenges Related to Cell and Advanced Therapies Supply Chain
Figure 3.8. Key Considerations for Transportation of Cell and Advanced Therapies
Figure 3.9. Temperature Variations across Cryogenic Vessels / Dewars for Storage of Cell and Advanced Therapies
Figure 3.10. Recommendations for Process Qualification of Cell and Advanced Therapies
Figure 3.11. Overview of Supply Chain Orchestration Platforms
Figure 3.12. Functions of Key Software Solutions for Cell and Advanced Therapies Supply Chain Management
Figure 3.13. Growth Drivers and Roadblocks to Software Solutions in Cell and Advanced Therapies Supply Chain
Figure 4.1. Cell and Advanced Therapies Supply Chain Management: Distribution by Type of Software Solution
Figure 4.2. Cell and Advanced Therapies Supply Chain Management: Distribution by Key Specifications and Benefits
Figure 4.3. Cell and Advanced Therapies Supply Chain Management: Distribution by Application
Figure 4.4. Cell and Advanced Therapies Supply Chain Management: Distribution by End User
Figure 4.5. Cell and Advanced Therapies Supply Chain Management: Distribution by Mode of Deployment
Figure 4.6. Cell and Advanced Therapies Supply Chain Management: Distribution by Scale of Management
Figure 4.7. Cell and Advanced Therapies Supply Chain Management: Distribution by Regulatory Certification / Accreditation
Figure 4.8. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Year of Establishment
Figure 4.9. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Geographical Location
Figure 4.10. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Company Size
Figure 4.11. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Services Offered
Figure 4.12. Leading Developers: Distribution by Number of Software Solutions
Figure 5.1. Competitiveness Analysis of Small-sized Supply Chain Management Software Solutions Providers
Figure 5.2. Competitiveness Analysis of Mid-sized Supply Chain Management Software Solutions Providers
Figure 5.3. Competitiveness Analysis of Large-sized Supply Chain Management Software Solutions Providers
Figure 6.1. Brooks Life Sciences: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 6.2. Cryoport: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 6.3. SAP: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 7.1. Standardization of Tasks by Supply Chain Orchestration Platforms
Figure 7.2. Key Functions of Supply Chain Orchestration Platforms
Figure 7.3. Advantages of Supply Chain Orchestration Platforms
Figure 7.4. Trends on Social Media: Historical Activity on Twitter, 2015-2018
Figure 7.5. Trends on Social Media: Popular Keywords
Figure 7.6. Be The Match BioTherapies®: Net Sales, FY 2013 – FY 2018 (USD Billion)
Figure 8.1. Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Figure 8.2. Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Figure 8.3. Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 8.4. Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Figure 8.5. Funding and Investments: Distribution by Type of Funding
Figure 8.6. Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 8.7. Popular Software Solutions: Distribution by Number of Funding Instances
Figure 8.8. Popular Software Solutions: Distribution by Amount Invested (USD Million)
Figure 8.9. Funding Instances: Year-wise Trend of Amount Invested across Different Software Solutions, 2014-Q3 2019 (USD Million)
Figure 8.10. Most Active Players: Distribution by Number of Instances
Figure 8.11. Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 8.12. Most Active Investors: Distribution by Number of Instances
Figure 8.13. Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 8.14. Funding and Investment Summary
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership 
Figure 9.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 9.4. Partnerships and Collaborations: Distribution by Partner’s Focus Area
Figure 9.5. Partnerships and Collaborations: Distribution by Type of Software Solution
Figure 9.6. Partnerships and Collaborations: Year-wise Trend by Type of Software Solution
Figure 9.7. Most Active Players: Distribution by Number of Partnerships
Figure 9.8. Most Active Players: Regional Distribution by Number of Partnerships
Figure 9.9. Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Figure 10.1. Platform Utilization Use Cases: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 10.2. Platform Utilization Use Cases: Distribution by User’s Focus Area
Figure 10.3. Platform Utilization Use Cases: Distribution by Type of Software Solution
Figure 10.4. Platform Utilization Use Cases: Year-wise Trend by Type of Software Solution
Figure 10.5. Most Active Players: Distribution by Number of Utilization Instances
Figure 10.6. Most Active Players: Regional Distribution by Number of Utilization Instances
Figure 11.1. Key Processes of Cell and Advanced Therapies Value Chain
Figure 11.2. Cell and Advanced Therapies Value Chain: Cost Distribution
Figure 11.3. Cell and Advanced Therapies Value Chain: Donor Eligibility Assessment
Figure 11.4. Cell and Advanced Therapies Value Chain: Sample Collection
Figure 11.5. Cell and Advanced Therapies Value Chain: Manufacturing
Figure 11.6. Cell and Advanced Therapies Value Chain: Logistics
Figure 11.7. Cell and Advanced Therapies Value Chain: Patient Verification and Treatment Follow-up
Figure 12.1. Cell and Advanced Therapies Supply Chain Management: Stakeholders Needs Analysis
Figure 12.2. Comparison of Stakeholder Needs 
Figure 13.1. Overall Cost Saving Potential of Supply Chain Management: Likely Scenarios
Figure 13.2. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 (USD Million)
Figure 13.3. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 13.4. Cost Saving Potential in Sample Collection, 2019-2030 (USD Million)
Figure 13.5. Cost Saving Potential in Manufacturing, 2019-2030 (USD Million)
Figure 13.6. Cost Saving Potential in Logistics, 2019-2030 (USD Million)
Figure 13.7. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030 (USD Million)
Figure 14.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, 2019-2030 (USD Million)
Figure 14.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.6. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030 (USD Million)
Figure 14.7. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.8. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, 2019-2030 (USD Million)
Figure 14.9. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030 (USD Million)
Figure 14.10. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, 2019-2030 (USD Million)
Figure 14.11. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, 2019-2030 (USD Million)
Figure 14.12. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030 (USD Million)
Figure 14.13. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, 2019-2030 (USD Million)
Figure 14.14. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, 2019-2030 (USD Million)
Figure 14.15. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.16. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.17. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.18. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.19. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.20. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.21. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.22. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, 2019-2030 (USD Million)
Figure 14.23. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.24. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030 (USD Million)
Figure 14.25. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, 2019-2030 (USD Million)
Figure 14.26. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030 (USD Million)
Figure 14.27. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030 (USD Million)
Figure 14.28. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030 (USD Million)
Figure 14.29. Patient Management Systems Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.30. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.31. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.32. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.33. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.34. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.35. Inventory Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.36. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.37. Inventory Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.38. Laboratory Information Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.39. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.40. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.41. Logistics Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.42. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.43. Logistics Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.44. Quality Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.45. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.46. Quality Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.47. Supply Chain Orchestration Platforms Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.48. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, 2019-2030
Figure 14.49. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, 2019-2030
Figure 14.50. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.51. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.52. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.53. Inventory Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.54. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.55. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.56. Laboratory Information Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.57. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.58. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.59. Quality Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.60. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.61. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.62. Supply Chain Orchestration Platforms Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.63. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, 2019-2030
Figure 14.64. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, 2019-2030
Figure 14.65. Logistics Management Systems Market for Logistics, 2019-2030 (USD Million)
Figure 14.66. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.67. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.68. Supply Chain Orchestration Platforms Market for Logistics, 2019-2030 (USD Million)
Figure 14.69. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
Figure 14.70. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
Figure 14.71. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.72. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.73. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.74. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.75. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.76. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 (USD Million)

List of Tables

Table 3.1. Applications of Cell and Advanced Therapies  
Table 3.2. Differences between Cell and Advanced Therapies and Biotechnology Products
Table 3.3. Cell and Advanced Therapies: Commercialized Products
Table 4.1. Cell and Advanced Therapies Supply Chain Management: Information on Type of Software Solution
Table 4.2. Cell and Advanced Therapies Supply Chain Management: Information on Key Software Specifications and Benefits
Table 4.3. Cell and Advanced Therapies Supply Chain Management: Information on Key Applications and End Users
Table 4.4. Cell and Advanced Therapies Supply Chain Management: Information on Mode of Deployment, Scale of Management and Key Regulatory Certifications / Accreditations
Table 4.5. Cell and Advanced Therapies Supply Chain Management: Developer Overview
Table 4.6. Cell and Advanced Therapies Supply Chain Management: Information on key Support Services Offered
Table 6.1. Brooks Life Sciences: Key Highlights
Table 6.2. Brooks Life Sciences: Key Characteristics of BiobankPro®
Table 6.3. Brooks Life Sciences: Recent Developments and Future Outlook
Table 6.4. Cryoport: Key Highlights
Table 6.5. Cryoport: Key Characteristics of Cryoportal®
Table 6.6. Cryoport: Recent Developments and Future Outlook
Table 6.7. MasterControl: Key Highlights
Table 6.8. MasterControl: Key Characteristics of MasterControl Platform™
Table 6.9. MasterControl: Recent Developments and Future Outlook
Table 6.10. SAP: Key Highlights
Table 6.11. SAP: Key Characteristics of SAP S/4HANA®
Table 6.12. SAP: Recent Developments and Future Outlook
Table 6.13. Savsu Technologies: Key Highlights
Table 6.14. Savsu Technologies: Funding Instances
Table 6.15. Savsu Technologies: Key Characteristics of evo® Cold Chain 2.0™
Table 6.16. Savsu Technologies: Recent Developments and Future Outlook
Table 6.17. TraceLink: Key Highlights
Table 6.18. TraceLink: Funding Instances
Table 6.19. TraceLink: Key Characteristics of Digital Supply Chain Platform
Table 6.20. TraceLink: Recent Developments and Future Outlook
Table 7.1. Be The Match BioTherapies®: Key Highlights
Table 7.2. Be The Match BioTherapies®: Key Characteristics of MatchSource®
Table 7.3. Be The Match BioTherapies®: Recent Developments and Future Outlook
Table 7.4. Clarkston Consulting: Key Highlights
Table 7.5. Clarkston Consulting: Key Characteristics of Cell Therapy Orchestration Platform
Table 7.6. Clarkston Consulting: Recent Developments and Future Outlook
Table 7.7. Haemonetics: Key Highlights
Table 7.8. Haemonetics: Key Characteristics of EdgeCell®
Table 7.9. Haemonetics: Recent Developments and Future Outlook
Table 7.10. Hypertrust Patient Data Care: Key Highlights
Table 7.11. Hypertrust Patient Data Care: Key Characteristics of Hypertrust X-Chain
Table 7.12. Hypertrust Patient Data Care: Recent Developments and Future Outlook
Table 7.13. Lykan Bioscience: Key Highlights
Table 7.14. Lykan Bioscience: Key Characteristics of Unnamed Cell Orchestration Platform
Table 7.15. Lykan Bioscience: Recent Developments and Future Outlook
Table 7.16. MAK-SYSTEM: Key Highlights
Table 7.17. MAK-SYSTEM: Key Characteristics of T.C.S.
Table 7.18. MAK-SYSTEM: Recent Developments and Future Outlook
Table 7.19. sedApta Group: Key Highlights
Table 7.20. sedApta Group: Key Characteristics of O.S.A.
Table 7.21. sedApta Group: Recent Developments and Future Outlook
Table 7.22. Stafa Cellular Therapy: Key Highlights
Table 7.23. Stafa Cellular Therapy: Key Characteristics of Stafa Cellular Therapy Lab
Table 7.24. Stafa Cellular Therapy: Recent Developments and Future Outlook
Table 7.25. Title 21 Health Solutions: Key Highlights
Table 7.26. Title 21 Health Solutions: Key Characteristics of Cell Therapy Software
Table 7.27. Title 21 Health Solutions: Recent Developments and Future Outlook
Table 7.28. TrakCel: Key Highlights
Table 7.29. TrakCel: Funding Instances
Table 7.20. TrakCel: Key Characteristics of TrakCel™ Cell Orchestration Platform
Table 7.31. TrakCel: Recent Developments and Future Outlook
Table 7.32. Vineti: Key Highlights
Table 7.33. Vineti: Funding Instances
Table 7.34. Vineti: Key Characteristics of Personalized Therapy Management Software
Table 7.35. Vineti: Recent Developments and Future Outlook
Table 8.1. Cell and Advanced Therapies Supply Chain Management: List of Funding Instances, 2014-Q3 2019
Table 8.2. Cell and Advanced Therapies Supply Chain Management: Summary of Investments
Table 9.1. Cell and Advanced Therapies Supply Chain Management: List of Partnerships, 2014-Q3 2019
Table 9.2. Most Active Players: Regional Distribution by Number of Partnerships
Table 10.1. Cell and Advanced Therapies Supply Chain Management: List of Platform Utilization Use Cases, 2014-Q3 2019
Table 15.1. Thermo Fisher Scientific: Key Highlights
Table 15.2. Cell and Gene Therapy Catapult: Key Highlights
Table 15.3. McKesson: Key Highlights
Table 15.4. TrakCel: Key Highlights
Table 16.1. Cell and Advanced Therapies Supply Chain Management: Key Takeaways of the Report
Table 17.1. List of Additional Supply Chain Management Software Solutions
Table 19.1. Cell and Advanced Therapies Supply Chain Management: Distribution by Type of Software Solution
Table 19.2. Cell and Advanced Therapies Supply Chain Management: Distribution by Key Specifications and Benefits
Table 19.3. Cell and Advanced Therapies Supply Chain Management: Distribution by Application
Table 19.4. Cell and Advanced Therapies Supply Chain Management: Distribution by End User
Table 19.5. Cell and Advanced Therapies Supply Chain Management: Distribution by Mode of Deployment
Table 19.6. Cell and Advanced Therapies Supply Chain Management: Distribution by Scale of Management
Table 19.7. Cell and Advanced Therapies Supply Chain Management: Distribution by Regulatory Certification / Accreditation
Table 19.8. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Year of Establishment
Table 19.9. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Geographical Location
Table 19.10. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Company Size
Table 19.11. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Services Offered
Table 19.12. Leading Developers: Distribution by Number of Software Solutions
Table 19.13. Brooks Life Sciences: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.14. Cryoport: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.15. SAP: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.16. Trends on Social Media: Historical Activity on Twitter, 2015-2018
Table 19.17. Be The Match BioTherapies®: Net Sales, FY 2013 – FY 2018 (USD Billion)
Table 19.18. Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Table 19.19. Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Table 19.20. Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.21. Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Table 19.22. Funding and Investments: Distribution by Type of Funding
Table 19.23. Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 19.24. Popular Software Solutions: Distribution by Number of Funding Instances
Table 19.25. Popular Software Solutions: Distribution by Amount Invested (USD Million)
Table 19.26. Funding Instances: Year-wise Trend of Amount Invested across Different Software Solutions, 2014-Q3 2019 (USD Million)
Table 19.27. Most Active Players: Distribution by Number of Instances
Table 19.28. Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 19.29. Most Active Investors: Distribution by Number of Instances
Table 19.30. Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 19.31. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.32. Partnerships and Collaborations: Distribution by Type of Partnership 
Table 19.33. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 19.34. Partnerships and Collaborations: Distribution by Partner’s Focus Area
Table 19.35. Partnerships and Collaborations: Distribution by Type of Software Solution
Table 19.36. Partnerships and Collaborations: Year-wise Trend by Type of Software Solution
Table 19.37. Most Active Players: Distribution by Number of Partnerships
Table 19.38. Most Active Players: Regional Distribution by Number of Partnerships
Table 19.39. Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Table 19.40. Platform Utilization Use Cases: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.41. Platform Utilization Use Cases: Distribution by User’s Focus Area
Table 19.42. Platform Utilization Use Cases: Distribution by Type of Software Solution
Table 19.43. Platform Utilization Use Cases: Year-wise Trend by Type of Software Solution
Table 19.44. Most Active Players: Distribution by Number of Utilization Instances
Table 19.45. Most Active Players: Regional Distribution by Number of Utilization Instances
Table 19.46. Cell and Advanced Therapies Value Chain: Cost Distribution
Table 19.47. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 (USD Million)
Table 19.48. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030 (USD Million)
Table 19.49. Cost Saving Potential in Sample Collection, 2019-2030 (USD Million)
Table 19.50. Cost Saving Potential in Manufacturing, 2019-2030 (USD Million)
Table 19.51. Cost Saving Potential in Logistics, 2019-2030 (USD Million)
Table 19.52. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Table 19.53. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Conservative Scenario, 2019-2030 (USD Million)
Table 19.54. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Base Scenario, 2019-2030 (USD Million)
Table 19.55. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.56. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Conservative Scenario, 2019-2030 (USD Million)
Table 19.57. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Base Scenario, 2019-2030 (USD Million)
Table 19.58. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.59. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.60. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.61. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.62. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.63. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.64. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.65. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.66. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.67. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.68. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.69. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.70. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.71. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.72. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.73. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.74. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Conservative Scenario, 2019-2030 (USD Million)
Table 19.75. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Base Scenario, 2019-2030 (USD Million)
Table 19.76. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.77. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Conservative Scenario, 2019-2030 (USD Million)
Table 19.78. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Base Scenario, 2019-2030 (USD Million)
Table 19.79. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.80. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Conservative Scenario, 2019-2030 (USD Million)
Table 19.81. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Base Scenario, 2019-2030 (USD Million)
Table 19.82. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.83. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Conservative Scenario, 2019-2030 (USD Million)
Table 19.84. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Base Scenario, 2019-2030 (USD Million)
Table 19.85. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.86. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Conservative Scenario, 2019-2030 (USD Million)
Table 19.87. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Base Scenario, 2019-2030 (USD Million)
Table 19.88. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.89. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Conservative Scenario, 2019-2030 (USD Million)
Table 19.90. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Base Scenario, 2019-2030 (USD Million)
Table 19.91. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.92. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Conservative Scenario, 2019-2030 (USD Million)
Table 19.93. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Base Scenario, 2019-2030 (USD Million)
Table 19.94. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.95. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.96. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.97. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.98. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.99. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.100. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.101. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.102. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.103. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.104. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.105. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.106. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.107. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.108. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.109. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.110. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.111. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.112. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.113. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.114. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.115. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.116. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.117. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Base Scenario, 2019-2030 (USD Million)
Table 19.118. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.119. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.120. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.121. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.122. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.123. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.124. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.125. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 19.126. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 19.127. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.128. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Conservative Scenario, 2019-2030 (USD Million)
Table 19.129. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Base Scenario, 2019-2030 (USD Million)
Table 19.130. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.131. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Conservative Scenario, 2019-2030 (USD Million)
Table 19.132. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Base Scenario, 2019-2030 (USD Million)
Table 19.133. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.134. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Conservative Scenario, 2019-2030 (USD Million)
Table 19.135. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Base Scenario, 2019-2030 (USD Million)
Table 19.136. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.137. Patient Management Systems Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.138. Patient Management Systems Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.139. Patient Management Systems Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.140. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.141. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.142. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.143. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.144. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.145. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.146. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.147. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.148. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.149. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.150. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.151. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.152. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.153. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.154. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.155. Inventory Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.156. Inventory Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.157. Inventory Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.158. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.159. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.160. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.161. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.162. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.163. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.164. Laboratory Information Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.165. Laboratory Information Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.166. Laboratory Information Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.167. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.168. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.170. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.171. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.172. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.173. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.174. Logistics Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.175. Logistics Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.176. Logistics Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.177. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.178. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.179. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.180. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.181. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.182. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.183. Quality Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.184. Quality Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.185. Quality Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.186. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.187. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.188. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.189. Quality Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.190. Quality Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.191. Quality Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.192. Supply Chain Orchestration Platforms Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.193. Supply Chain Orchestration Platforms Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.194. Supply Chain Orchestration Platforms Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.195. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.196. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.197. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.198. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.199. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.200. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.201. Enterprise Manufacturing Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.202. Enterprise Manufacturing Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.203. Enterprise Manufacturing Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19. 204. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19. 205. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19. 206. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19. 207. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19. 208. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19. 209. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.210. Inventory Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.211. Inventory Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.212. Inventory Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.213. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.214. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.215. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.216. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.217. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.218. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.219. Laboratory Information Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.220. Laboratory Information Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.221. Laboratory Information Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.222. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.223. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.224. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.225. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.226. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.227. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.228. Quality Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.229. Quality Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.230. Quality Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.231. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.232. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.233. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.234. Quality Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.235. Quality Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.236. Quality Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.237. Supply Chain Orchestration Platforms Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.238. Supply Chain Orchestration Platforms Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.239. Supply Chain Orchestration Platforms Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.240. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.241. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.242. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.243. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.244. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.245. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.246. Logistics Management Systems Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.247. Logistics Management Systems Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.248. Logistics Management Systems Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.249. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.250. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.251. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.252. Logistics Management Systems Market for Logistics: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.253. Logistics Management Systems Market for Logistics: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.254. Logistics Management Systems Market for Logistics: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.255. Supply Chain Orchestration Platforms Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.256. Supply Chain Orchestration Platforms Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.257. Supply Chain Orchestration Platforms Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.258. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.259. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.260. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.261. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.262. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.263. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.264. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.265. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.266. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.267. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.268. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.269. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.270. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.271. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.272. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.273. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.274. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.275. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.276. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.277. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.278. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.279. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.280. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.281. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3P Biopharmaceuticals
  2. 4G Clinical 
  3. ABB
  4. Abbott Informatics
  5. Accenture
  6. Adaptimmune Therapeutics
  7. Adents
  8. Adlib
  9. Advanced Therapy Treatment Centres
  10. Aegis
  11. ÅF Industry
  12. Agaram Technologies
  13. AgiLab
  14. AgileBio
  15. Aithent
  16. Alberta Cell Therapy Manufacturing
  17. AllCells
  18. AlloSource
  19. Alvotech
  20. Ambry Genetics
  21. Amgen
  22. Antares Vision
  23. Anterogen
  24. AntTail
  25. AODocs
  26. Aptean
  27. AQ Manager
  28. Aqxolt
  29. ArisGlobal
  30. ArunA Biomedical
  31. AssurX
  32. Asymptote
  33. Atara Biotherapeutics
  34. Atomos Hyla
  35. Aurea
  36. Autodesk
  37. Autolus Therapeutics
  38. Autoscribe Informatics
  39. AveXis
  40. Avita Medical
  41. Baptist Memorial Health Care
  42. BatchMaster Software
  43. BayaTree
  44. BC Platforms
  45. Benchling
  46. Benchmark
  47. Bika Lab Systems
  48. BioCision
  49. BioFortis
  50. Biokin Pharmaceutical
  51. BioLife Solutions
  52. BioSoft Integrators
  53. Biovault
  54. BIOVIA
  55. Birlasoft
  56. BizzMine
  57. Blaze Systems
  58. Blood Bank of Alaska
  59. Bluechiip
  60. bluecrux
  61. Boyum IT Solutions
  62. Bregal Sagemount
  63. Bristol-Myers Squibb
  64. Broekman Group
  65. Brooks Life Sciences
  66. Business Pointers
  67. Caladrius Biosciences
  68. Cambridge Biomedical
  69. Cambridge University Hospitals NHS Foundation Trust
  70. Camelot ITLab
  71. Camstar Systems
  72. Canaan Partners
  73. Canadian Tissue Repository Network
  74. CancerCare Manitoba
  75. Capgemini
  76. CareDx
  77. CareMetx
  78. Casdin Capital
  79. Cell and Gene Therapy Catapult
  80. Celularity
  81. Celyad
  82. Cenetron Diagnostics
  83. Cerner
  84. ChartFill
  85. Chiesi Farmaceutici
  86. Chiyoda System Technologies
  87. CIMx
  88. Clarkston Consulting
  89. Cleveland Institute for Computational Biology
  90. Clinical Ink
  91. CloudLIMS
  92. CobbleStone Software
  93. Codon Software
  94. Cognate BioServices
  95. Comaiba
  96. Conatus Pharmaceuticals
  97. Concerto Cloud Services
  98. Consummate Technologies
  99. Continental Technology Solutions
  100. COPAN Group
  101. CORDET
  102. Core Informatics
  103. COSMO CONSULT
  104. CoverMyMeds
  105. Credit Suisse
  106. CRISPR Therapeutics
  107. Cryo Store
  108. Cryogene Partners
  109. CRYO-LEA
  110. Cryoport
  111. CryoStem
  112. CryoTrack
  113. CSAM
  114. CSL Plasma
  115. Cubixx Solutions
  116. Cytolon
  117. Dacos
  118. Daedalus Software
  119. Daiichi Sankyo 
  120. Data+ Research
  121. DataArt
  122. Database Integrations
  123. Databyrån
  124. Datacor
  125. Dataworks Development
  126. Deacom
  127. Dell
  128. Deloitte
  129. Deltek
  130. Dendreon
  131. Deutsche Telekom
  132. DFJ
  133. DHL
  134. Digi-Trax
  135. DiscGenics
  136. Docbyte
  137. Docxellent
  138. Dooile
  139. Draper Associates
  140. eHealth Technologies
  141. EJADA
  142. Elinext
  143. Emad Trade House
  144. Emerson
  145. Endodiag
  146. Enhanced Information Solutions
  147. Enterprise System Partners
  148. Epeius Biotechnologies
  149. EuSoft
  150. EVERSANA™
  151. EXB Software
  152. Excellis Health Solutions
  153. EXTEDO
  154. Extract Systems
  155. e-Zest
  156. Factorytalk
  157. Factumsoft
  158. Faubel
  159. FedEx
  160. Ferdinand Cabanne Biobank Center
  161. FFF Enterprises
  162. Fibrocell Science
  163. Fidelity Biosciences
  164. FirstMark Capital
  165. Fishbowl
  166. Fisher Clinical Services
  167. Florida Hospital Cancer Center
  168. Foch Hospital
  169. F-Prime Capital Partners
  170. Fred Hutchinson Cancer Research Center
  171. French Epinal-Remiremont hospital group
  172. Gamida Cell
  173. GE Healthcare
  174. GE Ventures
  175. GEFCO
  176. Gen9
  177. Genea Biomedx
  178. Genedata
  179. Geneva Systems
  180. Genohm
  181. GenoLogics
  182. Georgian Partners
  183. Gilead Sciences
  184. GlaxoSmithKline
  185. Goldman Sachs
  186. GPI Group
  187. Gradalis
  188. Green Cross LabCell
  189. Grenoble Alpes University Hospital
  190. Gulf Software Distribution
  191. Gustave Roussy
  192. Haemonetics
  193. Haier Biomedical
  194. HeapTrace Technology
  195. Heat Biologics
  196. HemaCare
  197. Hemasoft Software
  198. HighPoint Solutions
  199. HighRes Biosolutions
  200. Hitachi
  201. Holostem Advanced Therapies
  202. HP Enterprise Group
  203. Human Stem Cells Institute
  204. Hypertrust Patient Data Care
  205. IBM
  206. ICON
  207. Ideagen
  208. IDESS
  209. IFS
  210. Immetacyte
  211. Immudex
  212. ImmunoCellular Therapeutics
  213. Indiana University Health
  214. Infinity Group
  215. Informeleon
  216. Informeleon LifeScience Technologies
  217. INFORS HT
  218. Innovate UK
  219. Innovation Connections
  220. Institute of Medical Biology
  221. Intelex
  222. Interactive Biosoftware
  223. Interactive Software
  224. International Air Transport Association
  225. International Genetically Engineered Machine Foundation
  226. International Stem Cell
  227. Iovance Biotherapeutics
  228. IPERION
  229. IQity
  230. IQMS
  231. IQVIA
  232. iSpecimen®
  233. I-Track Software
  234. JAF Consulting
  235. JAGGAER
  236. Japan Tissue Engineering
  237. JD Edwards
  238. Jeena
  239. Jeeves Information Systems
  240. Jinfonet Software
  241. KAIROS
  242. Kayentis
  243. KCAS Bioanalytical and Biomarker Services
  244. KCSA Strategic Communications
  245. Kiadis Pharma 
  246. Kite Pharma
  247. KLATU Networks
  248. KLP Enterprises
  249. Kolon TissueGene
  250. Körber Medipak Systems
  251. Labcon
  252. Labii
  253. LabLogic Systems
  254. LabLynx
  255. LabVantage Solutions
  256. LabWare
  257. Larsen & Toubro Infotech
  258. Lead Edge Capital
  259. LifeConEx
  260. LifeForce Capital
  261. Limoges University Hospital
  262. Liventa Bioscience
  263. Llamawerx
  264. Logistyx Technologies
  265. Lonza
  266. Lynden International
  267. Magenta Therapeutics
  268. MAK-SYSTEM
  269. Management Science Associates 
  270. MARKEN
  271. Marker Therapeutics
  272. MasterControl
  273. Mayo Clinic
  274. Mazik Global
  275. McKesson
  276. MD Logistics
  277. Medable
  278. MedCision
  279. Medical Research Network
  280. Medical University of Graz
  281. Medidata
  282. Medipost
  283. MediSapiens
  284. Mediware Information Systems
  285. MedNet Solutions
  286. Mendix
  287. Menlo Ventures
  288. Mesoblast
  289. Microsoft
  290. MicroStrategy
  291. Miller-Keystone Blood Center
  292. Miltenyi Biotec
  293. MiMedx Group
  294. Mindteck
  295. Modul-Bio
  296. Moffitt Cancer Center
  297. MolMed
  298. Montefiore Medical Center
  299. Montrium
  300. Morphotek
  301. Mount Sinai Medical
  302. Mustang Bio
  303. MyCellHub
  304. National Blood Transfusion Centre
  305. National Health Service Blood and Transplant
  306. Neotrident
  307. NetSuite
  308. Network Scientific
  309. New York Presbyterian Hospital
  310. New York University Abu Dhabi
  311. Nohla Therapeutics
  312. Northern Alliance Advanced Therapies Treatment Centre
  313. Noshaq
  314. Nous Infosystems
  315. Novartis
  316. Novatek International
  317. NTT Data
  318. NuVasive
  319. Nymi
  320. Oak HC/FT
  321. Oasis Infotech
  322. Ocimum Biosolutions
  323. Octal IT Solution
  324. Octapharma
  325. Octaware
  326. Odoo
  327. OmniComm
  328. Oncobiomed
  329. OpenSpecimen
  330. OpenXcell
  331. Opexa Therapeutics
  332. OptiProERP
  333. Oracle
  334. Orthofix
  335. OSIsoft
  336. Osys
  337. OTTR Complete Transplant Management
  338. Oxford BioMedica
  339. PAREXEL
  340. Parsec
  341. Pathomation
  342. PCX International
  343. Perseus PCI
  344. Persistent Systems
  345. Peter MacCallum Cancer Centre
  346. Petrichor Healthcare Capital Management
  347. Pharmicell
  348. Pilgrim Quality Solutions
  349. Planet Innovation
  350. PleaseTech
  351. Polar Speed
  352. Polarion
  353. POMS
  354. Poseida Therapeutics
  355. PricewaterhouseCoopers
  356. prime4services
  357. Priority Software
  358. Priveq Investment Fund IV
  359. Pro-curo Software
  360. ProfitKey
  361. Progeny Genetics
  362. Progeny Software
  363. ProMab Biotechnologies
  364. ProteoGenex
  365. Proteus Technologies
  366. Q2 Solutions
  367. QCMedchain
  368. QIAGEN
  369. Qualio
  370. Quality by Design
  371. Qualityze
  372. Qualsys
  373. Quick Life Science Group
  374. Rand Group
  375. RareChannels
  376. Redefine
  377. Reflow
  378. Reliance Life Sciences
  379. Replica Sistemi
  380. Rfgen Software
  381. ROC IT Solutions
  382. Roche
  383. Rockwell Automation
  384. Rootstock Software
  385. Roslin Cells
  386. RURO
  387. Sage
  388. salamanderU
  389. salesforce.com
  390. Samsung BioLogics
  391. Sanaria
  392. Sanpower Group
  393. SAP
  394. SapioSciences
  395. Sapphire
  396. Sarah Cannon Blood Cancer Network
  397. Sarla Technologies
  398. Savsu Technologies
  399. SciMed Technologies
  400. Scottish National Blood Transfusion Service
  401. Section 32
  402. sedApta Group
  403. SeerPharma
  404. SemanticBits
  405. Sensire
  406. Sentry BioPharma Services
  407. Shanghai Sunway Biotech
  408. Shanghai Wellthinic Technology
  409. ShipChain
  410. Sibiono GeneTech
  411. Siemens
  412. Sintec
  413. Software Point
  414. SOLABS
  415. SolutionsMax
  416. Spark Therapeutics
  417. Sparta 
  418. SPC Consultants
  419. Specialised Therapeutics
  420. SPI Pharma
  421. STEINER
  422. Stem Cell Technology Centre
  423. Stemedica Cell Technologies
  424. STEMSOFT Software
  425. stemTrak
  426. Strategic Information Group
  427. SuprTecBox
  428. Suzuken
  429. Swinburne Universoty
  430. Synergy Resources
  431. SYSPRO
  432. Systec & Services
  433. SystImmune
  434. SZIENZ
  435. Tableau Software
  436. Takeda Pharmaceutical
  437. TECHNIDATA
  438. Telegraph Hill Partners
  439. Terumo
  440. Terumo BCT
  441. Tessa Therapeutics
  442. Thaddeus
  443. The CoFoundry
  444. The Faktory
  445. Thermo Fisher Scientific
  446. Thrive Capital
  447. TiGenix
  448. Tissue Solutions
  449. Titian Software
  450. Title21 Health Solutions
  451. Tmunity Therapeutics
  452. Total Specific Solutions
  453. Touchdown International
  454. Toyo Business Engineering
  455. TPG Capital
  456. TraceLink
  457. Triangle Research Labs
  458. Triumvirate Environmental
  459. TrueERP
  460. UMass Memorial Health Care System
  461. UNIGEN
  462. United Cargo®
  463. United Parcel Service
  464. Unity™ Lab Services
  465. University Cancer Institute
  466. University Hospitals of Strasbourg and Strasbourg University
  467. University of Bialystok
  468. University of Illinois
  469. University of Melbourne
  470. University of Minnesota's Molecular and Cellular Therapeutics Unit
  471. University of Sheffield
  472. ValueLabs
  473. Veeva Systems
  474. Velos
  475. Vericel
  476. Verse
  477. Versiti™
  478. Vestrics Solutions
  479. Vitro
  480. Vitrolife
  481. Vivaldi
  482. VMware
  483. Volition Capital
  484. Vulcan Capital
  485. WellSky™
  486. Werum IT Solutions
  487. WindMIL Therapeutics
  488. Woodfield Distribution
  489. WorkWise
  490. World Courier
  491. WuXi AppTec Advanced Therapies
  492. XynManagement
  493. Xyntek
  494. Y Combinator
  495. Yale-New Haven Hospital
  496. Yokogawa Solution Service
  497. ZenBio
  498. Zenith Technologies 

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com